leisure time -WSS

leisure time

author：leisure time 2025-10-02 11:09:26 - browse：3

Two people stare at a keyhole in a human head in between them, as the short-haired person on the left holds a key — first opinion coverage from STAT — Adobe

In many ways, psychiatry is still flying blind. People experiencing mental health conditions are prescribed various drugs until one (or a combination) finally works — a painful process that can take years. As a psychiatrist and neuroscientist, I became increasingly impatient and frustrated with this ineffective way of treating patients. This guided the core question behind my research: Can biology explain how people with the same psychiatric disorder respond differently to the same treatment?

Since I first began exploring this question more than a decade ago, mental illness has become a global epidemic. Despite significant efforts, progress in psychiatric drug development has remained disappointingly slow. There have been a few notable approvals in recent years, and a renewal of interest by Big Pharma, following a retreat from psychiatric research in the mid to late 2000s. But the landscape remains predominantly marked by failures and a dry drug development pipeline. Approved drugs follow the same pattern of prescribing via guesswork, with most patients not responding to a given drug. This cycle of trial-and-error drug development producing trial-and-error treatment arises from a simple source: We have not systematized a process for learning from our failures and successes.

Related: A ‘renaissance in neuroscience’ could deliver a fresh crop of psychiatric medicines

For example, take depression: While the rise of selective serotonin reuptake inhibitors (SSRIs) in the 1980s and 1990s seemed to provide a solution, seminal studies in the 2000s exposed fundamental limitations of our treatment options. Antidepressants are widely prescribed, but their efficacy relative to placebo is modest.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Merck drug for rare lung condition set for approval in U.S.

focus

WSS

Abortion pill case raises question: who can sue the FDA?

Scientists boost immune system in aging mice by making it youthful

Abortion pill case raises question: who can sue the FDA?

Supreme Court mifepristone arguments center on docs' right to sue

Roche subsidiary Foundation Medicine opens new headquarters

Scientists boost immune system in aging mice by making it youthful

hotspot

leisure time

Related: A ‘renaissance in neuroscience’ could deliver a fresh crop of psychiatric medicines

Wikipedia

Walensky prepares to leave CDC — and Congress — behind

Abortion pill case raises question: who can sue the FDA?

Drug repurposing or repositioning? The language matters

Covid vaccine financial winners and losers, from Pfizer to Novavax

BioMarin wins approval for gene therapy to treat hemophilia A

Oprah kicked off a national conversation on obesity. Let's have it

How to save PrEP access — and even expand it

States should stop sabotaging methadone treatment reform

Dobbs anniversary: the lost opportunity of abortion as health care

Why the world’s most expensive drug might be worth the price

explore

There's no autism epidemic. It's an autism diagnosis epidemic

Washington mulls new rules to avert another Change Healthcare

Readout LOUD podcast: mifepristone case, GLP

Covid vaccine financial winners and losers, from Pfizer to Novavax

Oprah kicked off a national conversation on obesity. Let's have it

Eliminate the waiting period for sterilization covered by Medicaid

knowledge

focus

hotspot

hotspot